Citigroup Maintains Buy on Sana Biotechnology, Lowers Price Target to $11

Benzinga · 1d ago
Citigroup analyst Samantha Semenkow maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $12 to $11.